• N. Engl. J. Med. · Apr 2021

    Letter

    Neutralizing Activity of BNT162b2-Elicited Serum.

    Pfizer and BioNTech reported that phase 3 trials of their mRNA SARS-COV-2 vaccine showed:

    • Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose.
    • Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration.
    • Vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent.
    • Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose.
    summary
    • Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R Fontes-Garfias, Kena A Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C Weaver, Alexander Muik, Ugur Sahin, Kathrin U Jansen, Xuping Xie, Philip R Dormitzer, and Pei-Yong Shi.
    • University of Texas Medical Branch, Galveston, TX.
    • N. Engl. J. Med. 2021 Apr 15; 384 (15): 1466-1468.

    no abstract available

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    This article appears in the collection: COVID-19 and mRNA Vaccines.

    Notes

    summary
    1

    Pfizer and BioNTech reported that phase 3 trials of their mRNA SARS-COV-2 vaccine showed:

    • Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose.
    • Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration.
    • Vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent.
    • Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose.
    Daniel Jolley  Daniel Jolley
    pearl
    1

    The Pfizer–BioNTech COVID-19 vaccine was 91% effective in preventing infection with SARS-CoV-2 in phase 3 trials.

    Daniel Jolley  Daniel Jolley
     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
988,657 articles already indexed!

We guarantee your privacy. Your email address will not be shared.